CRISPR & Cas Genes Market Size to Hit USD 14.65 Billion by 2032

The global CRISPR & Cas genes market size was valued at USD 2.58 billion in 2022 and is projected to surpass around USD 14.65 billion by 2032, expanding at a healthy CAGR of 19% from 2023 to 2032.

The global CRISPR & Cas genes market size accounted for USD 3.06 billion in 2023, According to Precedence Research. North America has held the maximum market share in 2022.

Key Insights:

• The biomedical segment achieved the highest market share of 90% in 2022.
• The product segment accounted for over 75% of revenue share in 2022.
• The pharmaceutical and biotechnology segment held the most market share in 2022.

Download the Sample Copy@ https://www.precedenceresearch.com/sample/1108

CRISPR, or Clustered Regularly Interspaced Palindromic Repeats, are specific sequences found in the bacterial genome. These sequences act as a form of the immune system, protecting against invading viruses. When combined with CRISPR-associated (Cas) proteins, particularly Cas9, these proteins function as molecular scissors, acting as an endonuclease to cut both strands of DNA.

The application of CRISPR in drug development and therapeutic procedures has been constrained by its tendency to generate off-target effects. These unintended alterations pose a significant hurdle in utilizing CRISPR for human gene editing, as they can result in undesired changes. Despite the uniqueness of CRISPR technology, rare errors in the intended target pose a potential challenge in human clinical applications. Recently identified anti-CRISPR proteins present a promising solution to address these issues, aiming to enhance the precision and safety of CRISPR technology in both research and medical applications.

North America’s regional strength in the global economy has positioned it as a leader. In the United States and Canada, various federal initiatives support research in agricultural biotechnology and the commercial release of CRISPR-based plant products. An encouraging factor for CRISPR use is that the USDA didn’t regulate the initial soybean products created with CRISPR technology. Moreover, significant investments by pharmaceutical and seed companies in strategies like acquisitions, partnerships, and collaborations contribute to the growth of the pharmaceutical and plant industries, thereby fueling demand for CRISPR technology.

Regional Stance:

The market for CRISPR and Cas genes in North America represented a significant revenue share in 2022 when compared to markets in other regions. The development of the CRISPR and cas genes sector in North America is predicted to be aided by the extraordinary application of cutting-edge technologies and the presence of industry leaders. In addition, positive government initiatives and an increase in the number of research collaborations are some of the variables predicted to accelerate market expansion. The United States has the highest revenue contribution due to its well-established healthcare system, reassuring healthcare regulations, and high frequency of chronic conditions.

The U.S. CRISPR & Cas genes market size is estimated to grow from USD 830 million in 2023 to reach around USD 3.96 billion by 2032, growing at a remarkable CAGR of 18.90% from 2023 to 2032.

Over the course of the projection period, Asia Pacific is anticipated to witness the strongest development. China holds a prominent position in the global CRISPR business and is gradually learning how to use genome editing to improve medical treatments. Several CRISPER-based clinical studies have been introduced by it, especially for the treatment of cancer. Currently, China is the country with the greatest number of clinical trials utilising CRISPR technology worldwide. Additionally, it is the owner of over 858 publicly accessible CRISPR patent applications, mostly related to agriculture and other fields. Moreover, these molecular tools for crop variation are used by more than 20 research groups in China to increase agricultural production. These factors are therefore anticipated to accelerate the growth of the Asia Pacific market.

Ask Here for Customization@ https://www.precedenceresearch.com/customization/1108

CRISPR & Cas Genes Market Scope

Growth Factors:

• Increasing investments from private entities and government sources to advance innovative therapies are significantly driving the growth of the CRISPR and Cas genes market. The collective focus on developing novel therapeutics, propelled by the rising prevalence of various genetic diseases and cancer, is a crucial factor expected to boost the progress of the CRISPR and Cas genes market. In the years to come. Furthermore, advancements in CRISPR technology are anticipated to drive demand in the market further in the upcoming years.

• For instance, presenting new clinical data on the investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001, for severe hemoglobinopathies, Vertex and CRISPR Therapeutics showcased the effectiveness of CRISPR technologies at the annual European Hematology Association Virtual Congress in May 2022. The increasing focus on genomics research and development will drive market growth in the coming years. CTX001 is currently under investigation in two ongoing clinical trials as a potential one-time curative therapy for patients dealing with Transfusion-Dependent Thalassemia (TDT) and severe Sickle Cell Disease (SCD).

• A November 2022 article in the Nature Journal highlighted that CRISPR gene editing allows researchers to modify immune cells to recognize specific altered proteins in a person’s tumors. These customized cells can safely be released into the body to identify and eliminate the targeted tumors. This personalized treatment approach offered by CRISPR technologies for chronic diseases such as cancer is anticipated to drive market growth in the foreseeable future.

• The biotechnology and pharmaceutical sector, contributing 48.8% to the total revenue, took the lead in the market in 2022. Pharmaceutical companies are increasingly adopting CRISPR-Cas9 to accelerate the development of advanced biological models for human diseases and hasten the discovery and validation of new therapeutic targets. This trend is anticipated to propel the industry forward, resulting in a robust clinical pipeline based on CRISPR gene-editing technology.
• Additionally, the growing popularity of cell and gene therapy is driving demand for CRISPR-based gene-editing techniques in creating innovative therapeutics. In response to this demand, contract research firms are expected to experience significant growth. The competition among companies, emphasizing speed and cost reduction, will likely shape the market for CRISPR in this domain.

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 650 460 3308

Market Potential:

The genome engineering segment of the market is expected to expand, driven by the rise in genomics research and development activities along with increased funding. For instance, an article published in Frontiers in May 2022 highlighted that CRISPR technology simplifies the introduction of specific mutations into mammalian cells to create loss-of-function phenotypes. The successful use of CRISPR for genome-wide screening has proven valuable in identifying host characteristics that restrict viral infections, establishing CRISPR as a powerful tool for exploring the functional genomics of virus-host interactions.

The market is anticipated to experience growth in the forecast period, boosted by the continuous launch of new products by market players. For instance, QIAGEN, a provider of sample and assay technologies for various research domains, announced the QIAprep CRISPR Kit and CRISPR Q-Primer Solutions launch on June 21, 2021. These innovations are designed to assist researchers in analyzing edited gene material, contributing to advancements in the field.

Numerous companies academic and research institutions are actively using genome engineering techniques to advance the development of new therapies and treatments. For instance, in December 2022, an assistant professor in biomedical engineering and computer science secured USD 1.9 million in awards from the National Institutes of Health for genome sequencing research. Additionally, the researcher received USD 120,000 from Complete Genomics, a company specializing in human genome sequencing. The segment is anticipated to experience growth in the forecast period, fueled by substantial funding granted to researchers for genome engineering-related projects.

Related Reports:

• DNA Synthesis Market: The global DNA synthesis market size accounted for USD 3.50 billion in 2022, and it is projected to be worth around USD 20.87 billion by 2032, with a compound annual growth rate (CAGR) of 19.6% from 2023 to 2032.
  
• Gene Synthesis Market: The global gene synthesis market size was reached at USD 2.10 billion in 2022 and is expected to hit around USD 17.99 billion by 2032, poised to grow at a CAGR of 23.97% from 2023 to 2032.
  
• Gene Expression Market: The global gene expression market size was exhibited at USD 12.19 billion in 2022 and is expected to surpass around USD 32.85 billion by 2032 with an enhanced CAGR of 10.42% during the forecast period 2023 to 2032.

• DNA Diagnostics Market: The global DNA diagnostics market size reached USD 12.46 billion in 2023 and is expected to hit around USD 20.1 billion by 2032, poised to grow at a CAGR of 4.9% during the forecast period from 2023 to 2032.

• DNA Synthesizer Market: The global DNA synthesizer market size was valued at USD 274.11 million in 2022 and is expected to reach around USD 1,070.02 million by 2032, poised to grow at a CAGR of 14.59% during the forecast period from 2023 to 2032.

Industry Spotlight:

• As of August 23, Amber Bio is pioneering multi-kilobase gene editing platforms to tackle previously challenging diseases. The company plans to advance an RNA editing platform, allowing a single drug to treat conditions with high allelic diversity, which is especially beneficial for patients with diseases caused by diverse mutations.

• In August 2023, CrisprBits, a biotech startup in Bengaluru specialising in CRISPR gene-editing technology, revealed a strategic partnership with Molbio Diagnostics in Goa. Their collaboration aims to transform point-of-care diagnostics by integrating CRISPR technology into Point-of-Care tests (POCTs).

• In February 2023, Vertex Therapeutics hinted at its launch strategy for the potential debut of the first CRISPR-based gene editing therapy. As the company approaches the final stages of a significant FDA submission, there is anticipation surrounding this groundbreaking development in rare disease treatment.

• In December 2022, a University of California researcher initiated a clinical trial titled “Transplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease.” The trial aims to assess hematopoietic stem cell transplantation (HSCT) using CRISPR/Cas9 edited red blood cells, referred to as CRISPR_SCD001 Drug Product.

Market Key Players:

• Caribou Biosciences, Inc.
• F. Hoffmann-La Roche Ltd.
• Cellectis
• AstraZeneca
• Editas Medicine, Inc.
• Addgene
• Egenesis
• Horizon Discovery Group Plc
• Intellia Therapeutics, Inc.
• Genscrip
• Danaher Corporation
• Lonza
• Merck KGaA
• Synthego
• Mammoth Biosciences
• Inscripta, Inc.
• Cibus
• New England BioLabs
• Takara Bio, Inc.

Company Synopsis

Cellectis

Cellectis is dedicated to meeting the global population’s increasing medical and food demands by employing its exclusive gene-editing technologies. In a recent announcement, AstraZeneca (AZ) revealed a collaboration and investment agreement with Cellectis. The goal is to expedite the development of therapeutics in various fields, such as oncology, immunology, and rare diseases. The potential value of this deal exceeds $2.2 billion.

AstraZeneca

AstraZeneca is a global biopharmaceutical company discovering, developing, and commercialising prescription medicines. Headquartered in London, the company operates in over 100 countries, primarily focusing on oncology, cardiovascular, respiratory, and immunology. AstraZeneca India’s Global Capability Centre (GCC) has collaborated with Sastra Deemed University in Thanjavur to create a curriculum focused on clinical research and development. This initiative is part of their three-year Memorandum of Understanding (MoU) with the university.

Market Segmentation

By Product & Service

• By Service
  • Microbial Gene Editing
  • Cell Line Engineering
  • gRNA Design
  • DNA Synthesis
• By Product
  • Design Tool
  • Kits & Enzymes
  • Libraries
  • Antibodies
  • Others

By Application

• Agricultural
• Biomedical
  • Functional Genomics
  • Genome Engineering
  • Disease Model Studies
  • Epigenetics
  • Others

End-use Outlook

• Contract Research Organizations (CROs),
• Academics & Government Research Institutes
• Biotechnology & Pharmaceutical Companies

By Regional Outlook

• North America
• Europe
• Asia Pacific
• Middle East & Africa
• Latin America

Browse Table of Contents: https://www.precedenceresearch.com/table-of-content/1108

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Immediate Delivery Available | Buy This Premium Research Report@ https://www.precedenceresearch.com/checkout/1108

Unlocking Market Insights through Data Excellence

The “Precedence Statistics” flexible dashboard is a powerful tool that offers real-time news updates, economic and market forecasts, and customizable reports. It can be configured to support a wide range of analysis styles and strategic planning needs. This tool empowers users to stay informed and make data-driven decisions in various scenarios, making it a valuable asset for businesses and professionals looking to stay ahead in today’s dynamic and data-driven world.

Access our Premium Real Time Data Intelligence Tool, Visit: www.precedencestatistics.com

About Us

Precedence Research is a worldwide market research and consulting organization. We give an unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.

Web: https://www.precedenceresearch.com/

Our Blogs:

https://www.towardshealthcare.com

https://www.towardspackaging.com

For Latest Update Follow Us:

Linkedin | Facebook | Twitter